SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. Kottschade LA, Pond GR, Olszanski AJ, Zakharia Y, et al. Clin Cancer Res 2023 Mar 31:CCR-22-3207. doi: 10.1158/1078-0432.CCR-22-3207.

Read + Share

Amedeo Smart

Independent Medical Education

Kottschade LA, Pond GR, Olszanski AJ, Zakharia Y, et al. SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma. Clin Cancer Res 2023 Mar 31:CCR-22-3207. doi: 10.1158/1078-0432.CCR-22-3207.
PMID: 37000165